Inventiva (IVA) - Company Gross Revenue

Corporate emblem and logo of Inventiva (IVA)

Inventiva S.A. (IVA) is seeking a global partner to bring its drugs to market while avoiding mergers. High biotech costs and stringent FDA oversight create significant barriers. The company's sales time series on the GURU.Markets platform demonstrates revenue dynamics, where the 0.00 level reflects the current magnitude. The firm is developing oral medications, focusing on the therapy of fibrosis and metabolic liver disorders.

Inventiva Corp - IVA Company Sales (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Inventiva S.A.

- share price and expert price forecast:
Price Performance Chart Inventiva Corp|IVA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Inventiva S.A.|IVA - Total Company Value
- book capitalization data:
Equity per Share Inventiva|IVA - Company Net Assets|Market Value to Book Value Ratio inventivapharma.com|IVA - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Inventiva S.A.|IVA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Inventiva SA|IVA - Company Total Debt|Debt to Book Capital Inventiva S.A.|IVA - Company Long-Term Debts|Short-Term Debt Volume Inventiva|Quick Liquidity inventivapharma.com
- financial results and valuation multiples details:
IVA - Net Profit|Projected Future Earnings Inventiva S.A.|IVA - Price to Earnings Ratio|Future Price to Earnings Multiple inventivapharma.com|IVA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Inventiva S.A.|IVA - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Inventiva|IVA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth inventivapharma.com|IVA - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Inventiva S.A.
- issuer revenue and sales details:
IVA - Revenue and Sales Volume|Company Future Sales Inventiva Corp|IVA - Market Cap to Revenue|Price-to-Projected Revenue Ratio Inventiva S.A.
General company analysis:Inventiva Corp, IVA
Original product of Inventiva Corp

Inventiva S.A. is optimizing its biotechnological developments through ESG standards by minimizing laboratory waste. The company's current sales level reflects the pace of its operational business expansion in the US market. This indicator measures real revenue volume, allowing for an assessment of the issuer's market share retention. Analysis of the chart's dynamics reveals a risk of price stagnation should revenue growth slow. High turnover does not preclude volatility in the event of a shortage of market liquidity.

Key competitors

ARWR: Company Sales Revenue|Revenue and Sales Volume MIRM|Company Gross Revenue Dynavax Technologies Corporation|Company Revenue Arbutus Biopharma Corporation ABUS|GYRE: Company Sales Volume|ASMB: Company Sales|GALT: Company Revenue|GNFT: Revenue and Sales Volume|Company Total Revenue DURECT (DRRX)|Company Revenue Aligos Therapeutics Inc.|Company Sales Volume BIVI (BioVie Pharma)|Company Sales GLMD (Galmed Pharmaceuticals)|Company Total Sales NDRA|Revenue and Sales Volume HEPA (Hepion Pharmaceuticals, Inc.)